Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Scripps patent discloses novel transthyretin amyloid inhibitors for amyloidosis

Sep. 8, 2006

Laquinimod reduces rate of inflammatory disease activity in MS patients

Sep. 8, 2006

Abuse resistant drug ELI-216 studied in phase II

Sep. 8, 2006

GSK reports on a novel candidate for histamine H3 antagonism in AD

Sep. 8, 2006

LX-6171 for cognitive disorders begins phase I study

Sep. 8, 2006

NDA for CIP-Tramadol ER accepted for review

Sep. 7, 2006

Coprimary endpoints not met in phase III trial of LidoPAIN

Sep. 7, 2006

Santhera and Juvantia collaborate on fipamezole for Parkinson's dyskinesia

Sep. 7, 2006

MAP-0004 studied for acute migraine headaches in new phase II trial

Sep. 7, 2006

Phase IIa study under way for MEM-1003 in bipolar disorder

Sep. 7, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...